Helix Biopharm (HBP.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 07/31
| 04-2018 | 01-2018 | 10-2017 | 07-2017 | 04-2017 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 770 | 1,641 | 3,175 | 897 | 1,323 |
| Receivables | 362 | 417 | 409 | 630 | 332 |
| TOTAL | $1,306 | $2,229 | $3,640 | $1,700 | $1,774 |
| Non-Current Assets | |||||
| PPE Net | 408 | 424 | 455 | 487 | 495 |
| TOTAL | $408 | $424 | $455 | $487 | $495 |
| Total Assets | $1,714 | $2,653 | $4,095 | $2,187 | $2,269 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 2,646 | 1,752 | 1,298 | 1,438 | 2,123 |
| Accrued Expenses | 534 | 696 | 585 | 722 | 1,645 |
| TOTAL | $3,221 | $2,492 | $1,966 | $2,204 | $3,768 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 41 | 44 | 83 | 44 | N/A |
| TOTAL | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $3,221 | $2,492 | $1,966 | $2,204 | $3,768 |
| Shareholders' Equity | |||||
| Common Shares | 124,436 | 124,099 | 123,691 | 120,681 | 118,969 |
| Retained earnings | -162,395 | -160,248 | N/A | -155,380 | -154,140 |
| Other shareholders' equity | 13,584 | 13,442 | -144,430 | 11,814 | 10,804 |
| TOTAL | $-1,507 | $161 | $2,129 | $-17 | $-1,499 |
| Total Liabilities And Equity | $1,714 | $2,653 | $4,095 | $2,187 | $2,269 |